US-based MicroAire Surgical Instruments has acquired NEOSYAD, a developer of technology for adipose tissue engineering.
France-based NEOSYAD recently gained CE marking under the European Union’s Medical Device Regulation (EU MDR) for its AdiMate device and Adipure single-use kit.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
AdiMate combines the processes of infiltration for liposuction, a common preparation for the procedure which involves the injection of a saline solution containing adrenaline into a patient’s body, and liposuction and adipose tissue preparation (lipofilling) into one system. Used in tandem with AdiMate, AdiPure purifies and concentrates adipose tissue before it is distributed into a patient’s body via a control pedal in lipofilling procedures.
MicroAire president Jerome Barrillon commented: “NEOSYAD’s expertise, innovative products, and dedication to advancing adipose tissue technologies perfectly align with our mission to enable better patient outcomes and support plastic surgeons worldwide.
“NEOSYAD’s advanced adipose tissue technology complements MicroAire’s existing portfolio and will help us accelerate our vision of expanding our leadership in the adipose tissue market.”
Financial terms of the acquisition were undisclosed.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNEOSYAD co-founder and president Regis Roche commented: “By ensuring a higher quality of purified fat and significantly reducing operating times, we enable surgeons to perform procedures with greater precision and efficiency.
“Together with MicroAire, we aim to make these advanced solutions more accessible to patients worldwide, offering them a safer, more effective option for restoring their confidence and well-being.”
According to a report by the American Society of Plastic Surgeons, the popularity of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) such as Novo Nordisk’s Wegovy are causing an uptick in demand for breast implant reductions and related cosmetic procedures.
The GLP-1-RA market is heavily dominated by Novo Nordisk’s Wegovy/Ozempic and Eli Lilly’s Zepbound/Mounjaro (tirzepatide). GlobalData predicts combined sales of Wegovy and Ozempic to reach $41.84bn in 2030.
In other downstream effects of GLP-1-RAs, speaking at the recent JP Morgan 2025 Healthcare conference in San Francisco, Gary Guthart, CEO of Intuitive Surgical, the maker of the famous Da Vinci surgical robotic system, said that GLP-1s’ impact on total bariatric surgery had been a “headwind” in the past year and that weight loss surgery as a whole had been “de-prioritised”.
